Nasdaq:ions NewsHere you can find up-to-the-minute news and analysis of the company that you are researching for potential. Ionis Pharmaceuticals (NASDAQ:IONS - Get Rating) was upgraded by Citigroup from a "sell" rating to a "neutral" rating in a report issued on Thursday, The Fly reports. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary. Shares of NASDAQ:IONS opened at $36. CARLSBAD, Calif. Ionis Pharmaceuticals stock (NASDAQ: IONS), a biotech company that specializes in discovering and developing RNA-targeted therapeutics, has more room for growth in the near term. Nasdaq provides updated worldwide news headlines. (IONS) Latest Stock News & Headlines - Yahoo Finance Industries U. (NASDAQ: IONS) was in 23 hedge funds' portfolios at the end of March. (Nasdaq: IONS) (the "Company"), today reported financial results for the first quarter of 2023. According to the last reported balance sheet, Ionis Pharmaceuticals had liabilities of US$259. Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 week High & Low. IONS IONS PRE-MARKET QUOTE IONS LATEST PRE MARKET You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq. Fintel reports that on May 4, 2023, Citigroup upgraded their outlook for Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral. (NASDAQ:IONS – Get Rating) by 17. On May 3, 2023, Ionis Pharmaceuticals, Inc. National Bank of Canada FI increased its position in shares of Ionis Pharmaceuticals, Inc. The analyst firm set a price target for 27. Fintel reports that on May 4, 2023, Citigroup upgraded their outlook for Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral. Nov 18, 2021, 13:30 ET. 00 in net income (profit) each year or ($1. (IONS) Stock Price, News, Quote & History - Yahoo Finance U. 6% on Thursday, following the lithium-producing giant's release of strong first-quarter 2023 results on the prior afternoon. 45 minutes ago · Testing conducted by UL's Fire Safety Research Institute (FSRI) demonstrates the potential explosive power of a lithium ion battery thermal runaway. Sales come in line with estimates. TD Asset Management Inc lowered its position in Ionis Pharmaceuticals, Inc. Shares of NASDAQ:IONS opened at $36. 12 Price as of April 28, 2023, 10:00 a. ET New Energy Vehicle Lithium Ion Battery Market report introduces market competition situation among the vendors and company profile, besides, market price. (NASDAQ:IONS) Analysts Just Made A Major Cut To Next Year's Estimates Feb 25. Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. The stock price of Ionis Pharmaceuticals (NASDAQ:IONS), a biotech company that specializes in discovering and developing RNA-targeted therapeutics, plunged 14% in yesterday's trade to its five. Ionis Pharmaceuticals (Nasdaq:IONS) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Ionis Pharmaceuticals NasdaqGS:IONS Stock Report Last Price US$35. 85 Buy Zone (Top/Bottom Range): $44. IONS | Complete Ionis Pharmaceuticals Inc. (IONS) Latest Stock News & Headlines - Yahoo Finance U. 69% from its latest reported closing price of 34. โรงแรมที่ดีที่สุด หนองกี่ ที่ Tripadvisor - ค้นหา รีวิวนักท่องเที่ยว ภาพถ่ายจริง และราคาจาก ที่พัก ใน หนองกี่, ไทย. NASDAQ:IONS opened at $37. 00 and set a "market perform" rating on the stock in a research report. Ionis Pharmaceuticals (Nasdaq:IONS) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Ionis Pharmaceuticals NasdaqGS:IONS Stock Report Last Price US$35. Fintel reports that on May 4, 2023, RBC Capital reiterated coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform recommendation. Ionis Pharmaceuticals ( NASDAQ: IONS) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the. The business's fifty day moving average price is $36. 45 minutes ago · Testing conducted by UL's Fire Safety Research Institute (FSRI) demonstrates the potential explosive power of a lithium ion battery thermal runaway inside a simulated residential two-car garage. Ionis Pharmaceuticals: An Innovative Leader in RNA-Based Technology Applications Seeking Alpha 18 hours ago Ionis Pharmaceuticals Q1 2023 Earnings Preview MarketBeat 3 days ago Analysts Set. IONS stockopened at $36. Fintel reports that on May 4, 2023, Needham reiterated coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy recommendation. 10/16/22 IONS Ionis Pharmaceuticals, Inc. The all time high for this statistic is 28. IONS stock opened at $35. -- ( BUSINESS WIRE )-- Industrial Logistics Properties Trust (Nasdaq: ILPT) today announced its financial results for the quarter ended March 31, 2023, which can be found at the. NasdaqGS:IONS Debt to Equity History May 5th 2023 How Strong Is Ionis Pharmaceuticals' Balance Sheet? According to the last reported balance sheet, Ionis Pharmaceuticals had liabilities of US$259. 00 million for the quarter, compared to analyst estimates of $160. 36 with a high forecast of $152. NASDAQ IONS opened at $35. Real time Ionis Pharmaceuticals (IONS) stock price quote, stock graph, news & analysis. The institutional investor owned 779,495 shares of the company's stock after selling 24,588 shares during the period. The intraday chart, the last-five real-time quotes and sales data. 08 and a 200 day simple moving average of $39. Magna is more than one of the. Nasdaq provides NLS Volume, Previous Close, Today's High & Low, and the 52 week High & Low. 1% in the fourth quarter, Holdings Channel. The average price target represents an increase of 38. So these liquid assets roughly match the total liabilities. The firm has a 50 day simple moving average of $36. Accordingly, we confirm that since the Default Announcement:. (NYSE American: KULR) (the "Company" or "KULR"), a leading energy management platform company accelerating the global. (NASDAQ:IONS - Get Rating) by 3. The new store and adjacent liquor store will open to the public at 8 a. (Nasdaq: IONS) today announced positive topline results from the 66-week analysis of the Phase 3 NEURO-TTRansform study of Ionis and AstraZeneca's eplontersen in patients with hereditary. NASDAQ:IONSopened at $36. Testing conducted by UL's Fire Safety Research Institute (FSRI) demonstrates the potential explosive power of a lithium. 06 billion P/E Ratio N/A Dividend Yield N/A Price Target $45. NasdaqGS:IONS Debt to Equity History May 5th 2023 How Strong Is Ionis Pharmaceuticals' Balance Sheet? According to the last reported balance sheet, Ionis Pharmaceuticals had liabilities of US$259. (IONS) Latest Stock News & Headlines - Yahoo Finance U. Operating expenses increased in the first quarter of 2023 compared to the prior year as planned, reflecting investments in advancing Ionis' pipeline, technology and go-to-market activities for eplontersen, olezarsen and donidalorsen. The forecasts range from a low of 24. houses, townhouses, commercial space, plots of land, affordable homes and luxury. News Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down Zacks • 3 days ago Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates Zacks • 5 days ago Earnings. Tracy Fuerst, Vice President, Corporate Communications & PR. In a report released today, Gena Wang from Barclays maintained a Hold rating on Ionis Pharmaceuticals ( IONS – Research Report ), with a price target of $37. The average price target is $52. 17, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and. 87 for the same period compares to -$0. Apr 28, 2023 (The Expresswire) -- 2023-2030 According to our Latest Research, New Energy Vehicle Lithium Ion. Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159. Find your next home among 103 listings for sale in Kabin Buri quickly and easily online. 04% change from the last price of $35. 70 and the Nasdaq slipped 13. Monia sold 24,651 shares of the firm's stock in a transaction that occurred on Monday, February 6th. 34%) (As of 04/28/2023 ET) Compare Today's Range $34. The MarketWatch News Department was not involved in the creation of this content. Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. 87) EPS for the quarter, topping the consensus estimate of ($1. 69, for a total transaction of $1,003,049. 30 Estimated Duration to Target: 131-139d Contract of Interest: $IONS 1/20/23 50Ionis Pharmaceuticals, Inc. (IONS) Stock Price, News, Quote & History - Yahoo Finance U. 0% during the 4th quarter, according to its most recent 13F filing with the. Shares of NASDAQ IONS traded up $0. According to the last reported balance sheet, Ionis Pharmaceuticals had liabilities of US$259. (NASDAQ:IONS) announced its earnings results on Wednesday, May, 3rd. Ionis Pharmaceuticals ( NASDAQ:IONS – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. NASDAQ: IONS Show Full Chart Chart Data Not Available Last close prices updated as of May 04, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price Overview Key Ratios Trading Information Last Close. 16 and a 200 day moving average price of $39. Ionis Pharmaceuticals (IONS) Stock Price, News & Info | The Motley Fool Please. Fintel reports that on May 4, 2023, Barclays maintained coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Equal-Weight recommendation. Ionis Pharmaceuticals (Nasdaq:IONS) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech Ionis Pharmaceuticals NasdaqGS:IONS Stock Report Last Price US$35. Testing conducted by UL's Fire Safety Research Institute (FSRI) demonstrates the potential explosive power of a lithium ion battery thermal runaway inside a simulated residential two-car garage. NASDAQ: IONS Show Full Chart Chart Data Not Available Last close prices updated as of May 04, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price Overview. Pursuant to NP 12-203, we are required to file bi-weekly default status reports in the form of news releases until the MCTO is revoked. Real time Ionis Pharmaceuticals (IONS) stock price quote, stock graph, news & analysis. NEWTON, Mass. Barclays Maintains Ionis Pharmaceuticals (IONS). IONS market cap is currently $5. Ionis Pharmaceuticals (NASDAQ: IONS) $35. Following the completion of the sale, the chief executive officer now. (IONS) Stock Price, News, Quote & History - Yahoo Finance U. Operating expenses increased in the first quarter of 2023 compared to the prior year as planned, reflecting investments in advancing Ionis' pipeline, technology and go-to-market activities for eplontersen, olezarsen and donidalorsen. , March 22, 2023 /PRNewswire/ -- Ionis (Nasdaq: IONS) today announced the outcome of the U. Fintel reports that on May 4, 2023, RBC Capital reiterated coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform recommendation. Real-Time Live ION ION NEWS HEADLINES ION News Headlines Back to ION Overview Trending ETFs QYLD Global X NASDAQ-100 Covered Call ETF $17. The firm has a market capitalization of $5. (NASDAQ:IONS – Get Rating) by 14. According to the last reported balance sheet, Ionis Pharmaceuticals had liabilities of US$259. In a report released today, Gena Wang from Barclays maintained a Hold rating on Ionis Pharmaceuticals ( IONS – Research Report ), with a price target of $37. 82 Volume 727,756 shs Average Volume 866,383 shs Market Capitalization $5. UFUA national secretary Greg McConville said the union welcomed the growing use of EVs and BESSs to reduce. Industry: Household Appliance Manufacturing , Ventilation, Heating, Air-Conditioning, and Commercial Refrigeration Equipment Manufacturing , Electrical Equipment, Appliance,. Ionis Pharmaceuticals (IONS) reported $131 million in revenue for the quarter ended March 2023, representing a year-over-year decline of 7. Ionis Pharmaceuticals ( NASDAQ: IONS) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the company's better-than-expected Q1. Ionis Pharmaceuticals Stock Up 2. The company has a fifty day moving average of $35. (NASDAQ:NASDAQ:IONS) Q1 2023 Earnings Conference Call May 3, 2023 11:30 AM ETCompany ParticipantsWade Walke - SVP, IRBrett Monia - CEORichard Geary - Chief. The stock had a trading volume of 319,719 shares, compared to its average volume of 942,093. 18, 2021 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. 3% Updated 26 Apr, 2023 Data Company Financials + 19 Analysts IONS Stock. Website. 77 million and a GAAP net loss of $46. Ionis Pharmaceuticals ( NASDAQ:IONS - Get Rating) last posted its earnings results on Wednesday, May 3rd. The average price target represents a 48. Nasdaq provides updated worldwide news headlines. 37) earnings per share (EPS) for the quarter,. The company has a 50 day moving average price of $36. Ionis Pharmaceuticals (IONS) Stock Price, News & Info | The Motley Fool Please ensure Javascript is enabled. The company has a fifty day simple moving average of $36. 7% in the fourth quarter, according to its most recent Form 13F filing. Cash and short-term investments of $2. stock news by MarketWatch. markets open in 3 hours 54 minutes -1. 84 and its two-hundred day moving average price is $40. discovers and develops RNA-targeted therapeutics in the United States. News Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down Zacks • 3 days ago Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates Zacks • 5 days ago Earnings. 0m in receivables that were due within 12 months. Xponance Inc. The latest price target for Ionis Pharmaceuticals ( NASDAQ: IONS) was reported by SVB Leerink on Thursday, February 23, 2023. The company has a 50-day moving average price of $36. Analyst Price Forecast Suggests 38. (NASDAQ: IONS ), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE. Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5. 3 billion at March 31, 2023 enables continued investment in creating. Ionis Pharmaceuticals ( NASDAQ: IONS) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the company's better-than-expected Q1. Shares of NASDAQ IONS traded up $0. 37) earnings per share for the quarter, topping analysts’ consensus estimates of ($1. Ionis Pharmaceuticals (NASDAQ: IONS) $35. NASDAQ IONS opened at $36. Nov 18, 2021, 13:30 ET CARLSBAD, Calif. In a report released today, Luca Issi from RBC Capital reiterated a Buy rating on Ionis Pharmaceuticals (IONS - Research Report), with a price target of $65. The stock had a trading volume of 319,719 shares, compared to its. Ionis Pharmaceuticals ( NASDAQ:IONS – Get Rating) last released its quarterly earnings data on Wednesday, February 22nd. NASDAQ IONS opened at $36. , March 22, 2023 /PRNewswire/ -- Ionis (Nasdaq: IONS) today announced the outcome of the U. Shares of NASDAQ IONS opened at $37. Fintel reports that on May 4, 2023, Wells Fargo maintained coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight recommendation. 87) EPS for the quarter, topping analysts' consensus estimates of ($1. The business earned $131 million during the quarter, compared to the consensus estimate of $126. The company has a quick ratio of 7. According to the last reported balance sheet, Ionis Pharmaceuticals had liabilities of US$259. View real-time stock prices and stock quotes for a full financial overview. Ionis Pharmaceuticals press release ( NASDAQ: IONS ): Q1 GAAP EPS of -$0. Testing conducted by UL's Fire Safety Research Institute (FSRI) demonstrates the potential explosive power of a lithium ion battery thermal runaway inside a simulated residential two-car garage. News Ionis (IONS) Q4 Earnings Top Estimates, Sales Lag, Stock Down Zacks • 3 days ago Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Misses Revenue Estimates Zacks • 5. Shares of NASDAQ IONS opened at $37. 67 and its two-hundred day moving average price is $38. Here you can find up-to-the-minute news and analysis of the company that you are researching for potential investment opportunities. SVB Leerink dropped their target price on Ionis Pharmaceuticals from $34. Shares of NASDAQ IONS traded up $0. NASDAQ:IONS Ionis Pharmaceuticals (IONS) News Today $35. Pursuant to NP 12-203, we are required to file bi-weekly default status reports in the form of news releases until the MCTO is revoked. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs. About Real-Time Quotes. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter ended March. 90) on an earnings per share basis. 29 during trading hours on Thursday, hitting $36. May 03, 2023, 07:00 ET QALSODY approved for SOD1-ALS; MAA under review in EU Reported positive. TD Asset Management Inc's holdings in Ionis Pharmaceuticals were worth $29,442,000 as of its […]. Full year 2022 earnings: EPS exceeds analyst expectations Feb 24. markets open in 8 hours 58 minutes S&P Futures 4,142. 00 expecting IONS to fall. Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5. Real-time stock quotes can be used. 04% Upside) Based on 14 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. Ionis Pharmaceuticals, Inc. The company's earnings came in at -$44. IONS Stock 12 Months Forecast $52. Ionis Pharmaceuticals ( NASDAQ:IONS – Get Rating) last released its earnings results on Wednesday, February 22nd. Announce Discontinuation of Vupanorsen Clinical Development Program. (STEM) revealed Loss for its first quarter that increased from last year and missed the Street estimates. Fintel reports that on May 4, 2023, Citigroup upgraded their outlook for Ionis Pharmaceuticals (NASDAQ:IONS) from Sell to Neutral. increased its position in shares of Ionis Pharmaceuticals, Inc. NASDAQ:IONS Ionis Pharmaceuticals (IONS) News Today $35. Ionis Pharmaceuticals, Inc. 0m due within 12 months, and liabilities of US$2. 22 Price as of May 5, 2023, 3:00 p. Ionis Pharmaceuticals Stock Up 2. Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Nasdaq provides updated worldwide news headlines. Fintel reports that on May 4, 2023, Wells Fargo maintained coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight recommendation. Financial results are summarized below: Financial Highlights Revenue for the first quarter of 2023 was in line with expectations and included revenue from numerous diverse sources. Ionis Pharmaceuticals, Inc. NASDAQ IONS opened at $35. Lithium-ion batteries can start fires and even explode if they ignite or overheat. The company re-affirms its previously issued financial guidance for 2023. The testing was completed in western Illinois in 2022. The business had revenue of $152. The Dow Jones dropped 46. Fintel reports that on May 4, 2023, RBC Capital reiterated coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform recommendation. (NASDAQ:IONS) announced its earnings results on Wednesday, May, 3rd. It is part of the Baan Saen Suk Village project in Nong Ki, Prachin Buri and was. Shares of NASDAQ:IONS opened at $36. "Our first quarter results were in line with our. (NASDAQ: IONS ), the leader in RNA-targeted therapies, announced today initiation of OASIS-HAE,. 37 million in revenue each year. Ionis Pharmaceuticals (NASDAQ: IONS) $36. The shares were sold at an average price of $40. Albemarle (NYSE: ALB) stock gained 1. Published: April 28, 2023 at 3:06 a. IONS investors should be aware of a decrease in. The firm's 50-day moving average price is $35. , May 3, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. The company has a debt-to-equity ratio of 2. As of April 24, 2023, the average one-year price target for Ionis. Ionis (IONS) reports a narrower-than-expected Q1 loss. Ionis reports first quarter 2023 financial results News provided by Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals, Inc. UFUA national secretary Greg McConville said the union welcomed the. Ionis Pharmaceuticals: An Innovative Leader in RNA-Based Technology Applications Seeking Alpha 18 hours ago Ionis Pharmaceuticals Q1 2023 Earnings Preview MarketBeat 3 days ago Analysts Set. NASDAQ:IONS Ionis Pharmaceuticals (IONS) News Today $35. CBS News Videos. The company has a debt-to-equity ratio of 2. Ionis Pharmaceuticals, Inc. Ionis reports first quarter 2023 financial results News provided by Ionis Pharmaceuticals, Inc. Based on Ionis Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $159. S&P News & Analysis Financial Health Valuation Podcast Episodes Earnings. Ionis Pharmaceuticals ( NASDAQ:IONS – Get Rating) last released its earnings results on Wednesday, February 22nd. NASDAQ:IONS Ionis Pharmaceuticals (IONS) News Today $35. 87) EPS for the quarter, topping. 07 and a debt-to-equity ratio of 2. (RTTNews) - Stem, Inc. SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- KULR Technology Group, Inc. 3% Updated 26 Apr, 2023 Data Company Financials + 19 Analysts IONS Stock Overview. 16 and its 200-day moving average price is $39. Based on the recent corporate insider activity of 53 insiders, corporate insider sentiment is negative on the stock. Afterward, the first 100 customers in line will receive a mystery. NASDAQ: IONS Show Full Chart Chart Data Not Available Last close prices updated as of May 04, 2023, 4:00 PM EST | USD | BATS BZX Real-Time Price Overview Key Ratios Trading Information Last Close. Ionis Pharmaceuticals has a 12 month low of. IONS has been the topic of a number of other research reports. CBS News Videos. Get the latest Ionis Pharmaceuticals Inc (IONS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Real time Ionis Pharmaceuticals (IONS) stock price quote, stock graph, news & analysis. The company earns $-269,720,000. Ionis Pharmaceuticals (IONS) reported $131 million in revenue for the quarter ended March 2023, representing a year-over-year decline of 7. Testing conducted by UL's Fire Safety Research Institute (FSRI) demonstrates the potential explosive power of a lithium ion battery thermal runaway inside a simulated residential two-car garage. Fintel reports that on May 4, 2023, Needham reiterated coverage of Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy recommendation. The stock’s 50-day moving average price is $36. This property is a 208 SqM house with 3 bedrooms and 2 bathrooms that is available for sale. (NASDAQ:IONS) Q4 2022 Earnings Call Transcript February 22, 2023 Operator: Good morning, and welcome to Ionis Pharmaceuticals Fourth Quarter and Full Year 2022. Ionis Pharmaceuticals ( NASDAQ: IONS) traded flat on Thursday after Citi upgraded the developer of RNA-targeted therapeutics to Neutral from Sell following the company's better-than-expected Q1. Ionis Pharmaceuticals (NASDAQ:IONS - Get Rating) In other news, CEO Brett P.